Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 9Dermatologic 3Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Lung Neoplasms 13Neoplasms 8Melanoma 6Neoplasm Metastasis 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Large Cell 2Carcinoma, Basal Cell 2Brain Neoplasms 2Advanced Non-Small Cell Lung Cancer 2Adenocarcinoma 2Vaccinia 1Uterine Neoplasms 1

Interventions

pembrolizumab 63Nivolumab 44atezolizumab 14Docetaxel 10Cyclophosphamide 10Paclitaxel 9Magnetic Resonance Spectroscopy 9Ipilimumab 9avelumab 8Specimen Handling 8durvalumab 7Radiosurgery 7Cetuximab 7spartalizumab 6Radiotherapy 6Immune Checkpoint Inhibitors 6Interleukin-2 5Carboplatin 5fludarabine 4cabozantinib 4Trastuzumab 4Sunitinib 4Psychiatric Rehabilitation 4Pemetrexed 4Oxaliplatin 4Fluorodeoxyglucose F18 4Everolimus 4Cisplatin 4Capecitabine 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × cemiplimab × Thoracic × Clear all
NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡